antibody

B-RAF (Ab-446) Antibody

MBS851098

0.1 mg

215 USD

polyclonal

rabbit

nonconjugated

human, mouse

western blot, ELISA, immunohistochemistry, enzyme immunoassay

Antibody

B-RAF (Ab-446) Antibody

B-RAF

B-RAF; B-RAF proto-oncogene serine/threonine-protein kinase; B-Raf proto-oncogene serine/threonine-protein kinase; BRAF; BRAF1; c-RMIL; EC 2.7.1.37; EC 2.7.11.1; kinase B-Raf; p94; RAFB1; RMIL; RMIL serine/threonine-protein kinase; v-Raf murine sarcoma viral oncogene homolog B1

serine/threonine-protein kinase B-raf; Serine/threonine-protein kinase B-raf; serine/threonine-protein kinase B-raf; 94 kDa B-raf protein; proto-oncogene B-Raf; v-raf murine sarcoma viral oncogene homolog B; v-raf murine sarcoma viral oncogene homolog B1; murine sarcoma viral (v-raf) oncogene homolog B1; B-Raf proto-oncogene serine/threonine-protein kinase (p94); B-Raf proto-oncogene, serine/threonine kinase; Proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1

B-RAF

BRAF; BRAF; NS7; BRAF1; RAFB1; B-RAF1; BRAF1; RAFB1

BRAF_HUMAN

Rabbit

Human, Mouse

766

B-RAF (Ab-446) antibody detects endogenous levels of total B-RAF protein.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Store at -20 degree C for 1 year

Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA)

WB: 1:500~1:1000, IHC: 1:50~1:100, ELISA: 1:40000

Reactivity Note: Human (Identities = 100%, Positives = 100%); Mouse (Identities = 100%, Positives = 100%)

Immunogen: The antiserum was produced against synthesized non-phosphopeptide derived from human B-RAF around the phosphorylation site of serine 446 (R-D-SP-S-D). Pathway: Phosphatases/Kinases

Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells; Autophagy antibody

Stephens R.M., Mol. Cell. Biol. 12:3733-3742(1992). Albert S., Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. Hillier L.W., Nature 424:157-164(2003). ------------------------------------------------------------------------------------------------------------------------------------------

33188459

NP_004324.2

NM_004333.4

P15056

84,437 Da

ARMS-mediated Activation Pathway (106466); Activation Of NMDA Receptor Upon Glutamate Binding And Postsynaptic Events Pathway (161033); Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Alcoholism Pathway (585563); Alcoholism Pathway (587116); B Cell Receptor Signaling Pathway (198909); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); CDC42 Signaling Events Pathway (137994)

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008]

BRAF: a tyrosine kinase-like kinase of the RAF family. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Frequently mutated in thyroid cancers, skin melanomas and at lower frequency in a wide range of human cancers. An activating mutation, mimicking phosphorylation of the activation loop, is seen in 60% of malignant melanoma samples. Raf mutations are generally exclusive to Ras activating mutations. Activating mutations are also seen in ~10% of colorectal cancers, in lung cancers and gliomas, and at a lower rate in several other tumors. Inactivating mutations are also seen and may result in activation of c-Raf and Erk. Mutations in B-Raf, MEK1 and MEK2 also associated with cardiofaciocutaneous syndrome, displaying morphological, cardiac and mental defects. Approved Inhibitor: Nexavar/Sorafenib. Protein type: Protein kinase, TKL; EC 2.7.11.1; Protein kinase, Ser/Thr (non-receptor); Kinase, protein; Oncoprotein; TKL group; RAF family. Chromosomal Location of Human Ortholog: 7q34. Cellular Component: neuron projection; mitochondrion; plasma membrane; cytosol; nucleus. Molecular Function: small GTPase binding; identical protein binding; protein serine/threonine kinase activity; protein binding; MAP kinase kinase kinase activity; protein heterodimerization activity; mitogen-activated protein kinase kinase binding; calcium ion binding; ATP binding; protein kinase activity. Biological Process: response to peptide hormone stimulus; positive T cell selection; fibroblast growth factor receptor signaling pathway; response to cAMP; nerve growth factor receptor signaling pathway; activation of MAPKK activity; CD4-positive, alpha beta T cell differentiation; somatic stem cell maintenance; protein heterooligomerization; MAPKKK cascade; positive regulation of peptidyl-serine phosphorylation; protein amino acid phosphorylation; regulation of cell proliferation; synaptic transmission; organ morphogenesis; myeloid progenitor cell differentiation; small GTPase mediated signal transduction; positive regulation of stress fiber formation; visual learning; negative regulation of neuron apoptosis; negative regulation of apoptosis. Disease: Noonan Syndrome 1; Lung Cancer; Noonan Syndrome 7; Leopard Syndrome 3; Cardiofaciocutaneous Syndrome 1

0.1 mg

215 USD